Prazosin hydrochloride [19237-84-4]

Prazosin hydrochloride (Vasoflex) reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. Prazosin hydrochloride is a synthetic piperazine derivative with hypotensive antiadrenergic properties, It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention.

Prazosin hydrochloride, CAS 19237-84-4

Description	Prazosin hydrochloride (Vasoflex) reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. Prazosin hydrochloride is a synthetic piperazine derivative with hypotensive antiadrenergic properties, It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention.
In vitro	Prazosin leads to a significant increase in VEGF concentration in endothelial cells and angiogenesis only if eNOS is present. Prazosin binds to the α1-adrenergic receptors that are present on smooth muscle cells surrounding all larger blood vessels. [1] Prazosin (0.1 nM) blocks the increases in perfusion pressure caused by electrical stimulation of the perimesenteric nerves but does not significantly reduce the vasomotor effect of exogenous noradrenaline. [2]
In vivo	Prazosin application leads to the expansion of the capillary system by modulation of the hemodynamic environment (flow rate, shear stress) in skeletal muscle. Prazosin induces angiogenesis in extensor digitorum longus (EDL) muscles of C57BL/6 mice but not eNOS-knockout mice. [1] Prazosin (0.5-2.0 mg/kg) blocks Yohimbine-induced reinstatement of food and alcohol seeking, as well as footshock-induced reinstatement of alcohol seeking in rats. [3] Prazosin (0.2 mg kg(-1) s.c.) causes an enhancement of a suppression of conditioned avoidance response in the presence of the dopamine D2 receptor antagonist raclopride (0.05-0.20 mg/kg s.c.) in rats. [4] Prazosin administration alone (1 mg/kg, s.c.) only slightly reduces horizontal activity during an initial 10 min measurement period, although it consistently reduces rearing in freely moving rats. Prazosin effectively suppresses the locomotor stimulation caused by either dose of MK-801 throughout the whole observation period in freely moving rats. [5]

Synonyms	Prazosin hydrochloride, Prazosin HCl, cp-12299-1, Peripress, Vasoflex, Minipress
Molecular Weight	419.86
Formula	C19H22ClN5O4
CAS No.	19237-84-4

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

Ethanol: 5 mM

DMSO: 55 mg/mL (131 mM)

References and Literature

1. Baum O, et al. Am J Physiol Heart Circ Physiol,2004, 287(5), H2300-H2308. 2. Donoso MV, et al. J Pharmacol Exp Ther,1997, 282(2), 691-698. 3. Lê AD, et al. Psychopharmacology (Berl),2011, 218(1), 89-99. 4. Wadenberg ML, et al. J Neural Transm, 2000, 107(10), 1229-1238. 5. Mathé JM, et al. Eur J Pharmacol,1996, 309(1), 1-11. 6. Bowden G D, Land K M, O'Connor R M, et al. High-throughput screen of drug repurposing library identifies inhibitors of Sarcocystis neurona growth[J]. International Journal for Parasitology: Drugs and Drug Resistance. 2018 Apr；8(1): 137-144.

Citations

1. Bowden G D, Land K M, O'Connor R M, et al. High-throughput screen of drug repurposing library identifies inhibitors of Sarcocystis neurona growth. International Journal for Parasitology: Drugs and Drug Resistance. 2018 Apr；8(1): 137-144